General information about company		
Scrip code*		524703
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE751D01014
Name of company		SANDU PHARMACEUTICALS LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2026
Date of end of financial year		31-03-2027
Date of board meeting when results were approved		14-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		04-11-2026
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Second quarter
Nature of report standalone or consolidated		Standalone
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Unaudited
Segment Reporting		Single segment
Description of single segment		Manufacture of ayurvedic medicine
Start date and time of board meeting		14-11-2026 16:00
End date and time of board meeting		14-11-2026 18:40
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable
Whether the company has any related party?		Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public		NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		13-02-2025
Indicate Company website link for updated RPT policy of the Company		https://sandu.in/wp-content/uploads/2025/04/policy-on-materiality-and-dealing-with-Related-Party-Transaction-13.02.2025-1.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		3
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Remark The Company has made default on loans and Debt securities for Q and half year ended 30th september 2026

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
	Date of start of reporting period	01-07-2026	01-04-2026	
	Date of end of reporting period	30-09-2026	30-09-2026	
	Whether results are audited or unaudited	Unaudited	Unaudited	
	Nature of report standalone or consolidated	Standalone	Standalone	
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**			
1	**Income**			
	Revenue from operations	1942.88	3581.76	
	Other income	8.71	10.44	
	Total income	**1951.59**	**3592.2**	
2	**Expenses**			
(a)	Cost of materials consumed	159.08	393.18	
(b)	Purchases of stock-in-trade	542.23	985.47	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	225.98	202.62	
(d)	Employee benefit expense	240.12	519.57	
(e)	Finance costs	2.6	5.59	
(f)	Depreciation, depletion and amortisation expense	16.55	32.92	
(g)	**Other Expenses**			
1	Other Expenses	679.12	1330.88	
	Total other expenses	**679.12**	**1330.88**	
	Total expenses	**1865.68**	**3470.23**	
3	**Total profit before exceptional items and tax**	**85.91**	**121.97**	
4	Exceptional items	0	0	
5	**Total profit before tax**	**85.91**	**121.97**	
6	**Tax expense**			
7	Current tax	20.4	29.78	
8	Deferred tax	-13.01	-9.15	
9	**Total tax expenses**	**7.39**	**20.63**	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	**Net Profit Loss for the period from continuing operations**	**78.52**	**101.34**	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	**Total profit (loss) for period**	**78.52**	**101.34**	
17	Other comprehensive income net of taxes	13.71	29.23	
18	**Total Comprehensive Income for the period**	**92.23**	**130.57**	
19	**Total profit or loss, attributable to**			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	**Total Comprehensive income for the period attributable to**			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	**Details of equity share capital**			
	Paid-up equity share capital	966.1	966.1	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	**Earnings per share**			

i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	0.68	1.05	
	Diluted earnings (loss) per share from continuing operations	0.68	1.05	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	0.68	1.05	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.68	1.05	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Text Block	
Textual Information(4)	1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017. 2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. “Ayurvedic Property Medicines”. Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed. 3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 14/11/2026. 4. The Figures for the quarter ended 30th Sept, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to Six months ended of the respective financial year.. 5. Figures for the previous periods have been reclassified/regrouped, whenever necessary. necessary.

Statement of Asset and Liabilities		
Particulars		Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	**Non-current assets**	
	Property, plant and equipment	848.22
	Capital work-in-progress	10.91
	Investment property	0
	Goodwill	0
	Other intangible assets	932.2
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	1242.31
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	
1	Other Non Current Assets	12.44
2		
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	**12.44**
	Total non-current financial assets	**1254.75**
	Deferred tax assets (net)	
	Other non-current assets	
1		
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	
	Total non-current assets	**3046.08**
2	**Current assets**	
	Inventories	1133.48
	Current financial asset	
	Current investments	0
	Trade receivables, current	783.04
	Cash and cash equivalents	314.27
	Bank balance other than cash and cash equivalents	83.72
	Loans, current	0
	Other current financial assets	
1	Other Current Assets	357.08
2		
3		
4		
5		

	Details of other current financial assets	
	Total of Other current financial assets	**357.08**
	Total current financial assets	**1538.11**
	Current tax assets (net)	
	Other current assets	
1		
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	
	Total current assets	**2671.59**
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	**5717.67**
	Equity and liabilities	
1	**Equity**	
	Equity attributable to owners of parent	
	Equity share capital	966.1
	Other equity	3435.2
	Total equity attributable to owners of parent	**4401.3**
	Non controlling interest	
	Total equity	**4401.3**
2	**Liabilities**	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	0
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1	Finance Lease Obligations	30.86
2	Deferred Tax Liabilities	141.63
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	**172.49**
	Total non-current financial liabilities	**172.49**
	Provisions, non-current	0
	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
1		
2		
3		
4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	**172.49**
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	0

	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	60.26
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	478.27
	Total Trade payable	**538.53**
	Other current financial liabilities	
1	Finance Lease Obligations	6.43
2	Other Financial Liabilities	39.75
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	**46.18**
	Total current financial liabilities	**584.71**
	Other current liabilities	
1	Other current liabilities	132.07
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	**132.07**
	Provisions, current	427.1
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	**1143.88**
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	**1316.37**
	Total equity and liabilities	**5717.67**
	Disclosure of notes on assets and liabilities	

Other Comprehensive Income			
	Date of start of reporting period	01-07-2026	01-04-2026
	Date of end of reporting period	30-09-2026	30-09-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Fair value changes of Investments	15.74	33.58
	Total Amount of items that will not be reclassified to profit and loss	15.74	33.58
2	Income tax relating to items that will not be reclassified to profit or loss	2.03	4.35
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	13.71	29.23

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	121.97
2	**Adjustments for reconcile profit (loss)**	
	Adjustments for finance costs	5.59
	Adjustments for decrease (increase) in inventories	-86.34
	Adjustments for decrease (increase) in trade receivables, current	-245.98
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-108.17
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	91.77
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	15.99
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	32.92
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	4.04
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	10.44
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	**-300.62**
	Net cash flows from (used in) operations	**-178.65**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	31.31
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	**-209.96**
3	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0

	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	5.39
	Proceeds from sales of investment property	47.77
	Purchase of investment property	12.51
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	10.44
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	**40.31**
4	**Cash flows from used in financing activities**	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	4.65
	Dividends paid	96.61
	Interest paid	5.59
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	**-106.85**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**-276.5**
5	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**-276.5**
	Cash and cash equivalents cash flow statement at beginning of period	590.77
	Cash and cash equivalents cash flow statement at end of period	**314.27**

Format for Disclosure of Related Party Transactions (applicable only for h

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Va tra du re p
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private Limited	AADCS9226L	Entities in which KMP are interested	Any other transaction	Balance Payable	10000	Approved by Board of directors and shareholders			2
2	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private Limited	AADCS9226L	Entities in which KMP are interested	Sale of goods or services		10000	Approved by Board of directors and shareholders			3
3	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private Limited	AADCS9226L	Entities in which KMP are interested	Purchase of goods or services		10000	Approved by Board of directors and shareholders			9
4	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Private Limited	AADCS9226L	Entities in which KMP are interested	Any other transaction	Royalty Paid	10000	Approved by Board of directors and shareholders			3
5	Sandu Pharmaceuticals Limited	AAACS6291G	Shri. Balram Viswanathan	AADPV1404C	Key Managerial Person	Remuneration			Approved by Board of directors and shareholders			1
6	Sandu Pharmaceuticals Limited	AAACS6291G	Shri Vijay Kajarekar	ADXPK1740P	Key Managerial Person	Remuneration			As per the terms of employement contract			
7	Sandu Pharmaceuticals Limited	AAACS6291G	Smt. Pratika Mhambray	CTQPS2943K	Key Managerial Person	Remuneration			As per the terms of employement contract			
Total value of transaction during the reporting period												1(

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	31-03-2021
Amount Raised	263.8
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NOT APPLICABLE
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	263.8	0	263.8	0	

Signatory Details	
Name of signatory	BALRAM VISWANATHAN
Designation of person	Managing Director
Place	Mumbai
Date	14-11-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	28-02-2022
Amount Raised	138.05
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NOT APPLICABLE
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	138.05	0	138.05	0	

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (3)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	14-07-2022
Amount Raised	131.95
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NOTAPPLICABLE
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	131.95	0	66.46	0	The Company has unutilized money lying in the Escrow account as on 30th September 2026 of which FD is created in the name of the Company in Bank of Baroda for utilizing amount as and when required.